An analysis of US enteric fever cases found that most travel-associated cases were not susceptible to the first-line antibiotic treatment, researchers with the Centers for Disease Control and Prevention (CDC) reported this week in JAMA Network Open.
Enteric fever, which encompasses both typhoid and paratyphoid fever, is typically transmitted via food or water contaminated with Salmonella Typhi or Paratyphi bacteria and can be deadly if not treated promptly with antibiotics.
Nearly 8 million enteric fever cases occur globally each year, but only a small fraction of those cases (5,700) occur in the United States, and they’re typically linked to travel to countries where typhoid and paratyphoid fever are endemic, such as India and Pakistan.
With new patterns of antibiotic resistance emerging globally, particularly in Pakistan, where an extensively drug-resistant (XDR) strain of Salmonella Typhi was identified in 2016, the researchers wanted to analyze US cases for antimicrobial-resistance trends.
“Because resistance can evolve quickly, surveillance is important to detect emerging resistance, track trends, and guide clinical and public health decision-making,” they wrote.
Empiric treatment ‘should avoid fluoroquinolones’
Using data from the National Typhoid and Paratyphoid Fever Surveillance system and bacterial samples from the National Antimicrobial Resistance Monitoring System (NARMS), the researchers identified 2,342 enteric fever cases reported from 47 states from 2016 to 2020.
Most patients (81.9%) reported traveling or residing internationally within 30 days of illness onset, with India, Pakistan, and Bangladesh the most common destinations.
Of the 1,635 enteric fever isolates that tested through NARMS, 78.4% of the Salmonella Typhi and 94.2% of the Paratyphi isolates were not susceptible to ciprofloxacin, which has been a first-line treatment since the 1980s. In addition, 5.5% of the Typhi isolates were resistant to ceftriaxone, although it was largely confined to travelers to Pakistan.
“These findings suggest that empiric treatment recommendations for enteric fever should avoid fluoroquinolones, as nonsusceptibility has been linked to poorer clinical outcomes,” the authors wrote, adding that treatment of enteric fever should be tailored to antibiotic susceptibility test results and patients’ travel history.
The authors also note that getting vaccinated for typhoid fever prior to travel could help reduce the number of US cases.